PharmaPoint: Hepatitis C Virus - Current and Future Players

NEW YORK, June 18, 2013 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

PharmaPoint: Hepatitis C Virus - Current and Future Players
http://www.reportlinker.com/p01360820/PharmaPoint-Hepatitis-C-Virus---Current-and-Future-Players.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology

PharmaPoint: Hepatitis C Virus - Current and Future Players

Summary

GlobalData has released its pharma report, "PharmaPoint: Hepatitis C Virus - Current and Future Players". The report is a vital source of up-to-date information with in-depth analysis on the companies in the rapidly growing HCV Market. The report identifies and analyses the key companies shaping and driving the global HCV market. The report provides insight into the competitive HCV landscape, including new companies entering the market. This report is built using data and information sourced from proprietary databases, primary and secondary and in-house analysis by GlobalData's team of industry experts.

Scope

- Investigation of current and future market competition for HCV
- Competitor assessment
- Coverage of key market players and company profiles including business description, financial overview and SWOT analysis.
- Strategic assessment of the HCV sector through market impact analysis, future market scenario and company analysis

Reasons to buy

- Gain a high level view of the trends shaping and driving the HCV Market
- Assess competitiveness of products in market by understanding the strengths and weaknesses of current competition.
- Create an effective counter-strategy to gain a competitive advantage against those currently in the market
- What's the next big thing in the global HCV market landscape? Identify, understand and capitalize

1 Table of Contents
1 Table of Contents 5
1.1 List of Tables 7
1.2 List of Figures 8
2 Introduction 9
2.1 Catalyst 9
2.2 Related Reports 9
2.3 Upcoming Related Reports 11
3 Market Outlook 12
3.1 Global Markets 12
3.1.1 Forecast 12
3.1.2 Drivers and Barriers – Global Issues 16
4 Current and Future Players 21
4.1 Overview 21
4.2 Trends in Corporate Strategy 23
4.3 Company Profiles 24
4.3.1 Merck 24
4.3.2 Roche 26
4.3.3 Vertex 28
4.3.4 Janssen 29
4.3.5 Gilead 31
4.3.6 AbbVie 34
4.3.7 Bristol-Myers Squibb 36
4.3.8 Boehringer Ingelheim 38
4.4 Additional Companies with Promising Drugs 40
4.4.1 Mitsubishi Tanabe 40
4.4.2 GlaxoSmithKline 41
4.4.3 Achillion 41
4.4.4 Scynexis 42
4.4.5 Idenix 43
4.4.6 Presidio 44
5 Appendix 45
5.1 Bibliography 45
5.2 Abbreviations 48
5.3 Methodology 49
5.4 Forecasting Methodology 49
5.4.1 Percent Drug-Treated Patients 49
5.4.2 Patient Warehousing 50
5.4.3 Drugs Included in Each Therapeutic Class 50
5.4.4 Launch and Patent Expiry Dates 51
5.4.5 General Pricing Assumptions 52
5.4.6 Individual Drug Assumptions 52
5.4.7 Generic Erosion 55
5.4.8 Selection of Pipeline Agents 55
5.4.9 Pricing of Pipeline Agents 56
5.5 Physicians and Specialists Included in this Study 59
5.6 Survey of Prescribing Physicians 61
5.7 About the Authors 62
5.7.1 Author 62
5.7.2 Epidemiologist 62
5.7.3 Global Head of Healthcare 63
5.8 About GlobalData 64
5.9 Contact Us 64
5.10 Disclaimer 64

List of Tables

Table 1: Global Sales Forecasts ($m) for HCV, 2012–2022 14
Table 2: HCV Market – Drivers and Barriers, 2013 16
Table 3: Key Companies in the HCV Market, 2012 22
Table 4: Merck's HCV Portfolio Assessment, 2012 25
Table 5: Merck SWOT Analysis, 2012 25
Table 6: Roche's HCV Portfolio Assessment, 2012 27
Table 7: Roche SWOT Analysis, 2012 27
Table 8: Vertex's HCV Portfolio Assessment, 2012 28
Table 9: Vertex SWOT Analysis, 2012 29
Table 10: Janssen's HCV Portfolio Assessment, 2012 30
Table 11: Janssen SWOT Analysis, 2012 31
Table 12: Gilead's HCV Portfolio Assessment, 2012 33
Table 13: Gilead SWOT Analysis, 2012 33
Table 14: AbbVie's HCV Portfolio Assessment, 2012 35
Table 15: AbbVie SWOT Analysis, 2012 35
Table 16: Bristol-Myers Squibb's HCV Portfolio Assessment, 2012 37
Table 17: Bristol-Myers Squibb SWOT Analysis, 2012 37
Table 18: Boehringer Ingelheim's HCV Portfolio Assessment, 2012 39
Table 19: Boehringer Ingelheim SWOT Analysis, 2012 39
Table 20: Mitsubishi Tanabe's HCV Portfolio Assessment, 2012 40
Table 21: GlaxoSmithKline's HCV Portfolio Assessment, 2012 41
Table 22: Achillion's HCV Portfolio Assessment, 2012 42
Table 23: Scynexis' HCV Portfolio Assessment, 2012 42
Table 24: Idenix's HCV Portfolio Assessment, 2012 43
Table 25: Presidio's HCV Portfolio Assessment, 2012 44
Table 26: Key Launch Dates 51
Table 27: Key Patent Expiries 51
Table 28: Physicians Surveyed, By Country 61

List of Figures

Figure 1: Global Sales for HCV Therapeutics by Region, 2012–2022 15
Figure 2: Company Portfolio Gap Analysis in HCV, 2012–2022 22

Companies Mentioned
Merck
Roche
Vertex
Janssen
Gilead
AbbVie
Bristol-Myers Squibb
Boehringer Ingelheim
Mitsubishi Tanabe
GlaxoSmithKline
Achillion
Scynexis
Idenix
Presidio

To order this report:
Pathology Industry: PharmaPoint: Hepatitis C Virus - Current and Future Players

Contact Clare: [email protected]  
US:(339) 368 6001
Intl:+1 339 368 6001

SOURCE Reportlinker